An observational study in Neonatal Encephalopathy, Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy) and Neonatal Encephalopathy, Unspecified, sponsored by CergenX Limited. Recruiting at 2 sites in 2 countries. Open to participants aged 36 Weeks and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by CergenX Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Hypoxia-Ischemia, Brain with a site in United States — 27 open to participants now, 34 under way, 1 of them phase 3. Hypoxia-Ischemia, Brain · United States.
Among the 84 studies in Hypoxia-Ischemia, Brain with a site in United States, this one is the 10th largest by planned enrollment of the 31 observational ones that give a count, is one of 6 that started in 2026, is one of 31 observational ones, reaches primary completion later than 21 of the 33 other live ones, and was the 84th registered.
261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.
Browse Hypoxia-Ischemia, Brain studies →27 of the 84 studies in Hypoxia-Ischemia, Brain with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 8 mo–24 mo
Artemis AI Labs · Sites in United States
Healthy volunteers
Healing Hope International · Sites in United States
Ages 4–12
Boston Children's Hospital · Sites in United States
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.
This study: 36 Weeks and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 14 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 89 across 92 observational studies indexed under Hypoxia-Ischemia, Brain.
Median enrollment 32 across the 52 interventional studies, 78 across the 31 observational. Of the 42 that completed or were terminated, 21 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 84 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with CergenX Limited as lead sponsor.
CergenX Limited has 1 study filed under Hypoxia-Ischemia, Brain — fewer than ten, so there is no comparison to draw.
17 of the studies in Hypoxia-Ischemia, Brain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05778188Phase 3ReAlta Life Sciences, Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia | 2026-12 |
| NCT05568264Shirley Ryan AbilityLabEffects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT05361070University of California, San FranciscoNeonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy | 2027-02-28 |
| NCT02621944University of FloridaMelatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia | 2027-03 |
Add all 17 to your calendar (.ics) → With an account.
Among the 84 studies in Hypoxia-Ischemia, Brain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.
A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.
The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Infants at high-risk of Neonatal Encephalopathy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a) A pH of 7.01-7.15 or base deficit of 10-15.9 (on cord or 1st infant blood gas at \< 1 hour of life) WITH b) at least one of the following:
An acute perinatal event:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neonates at risk of Neonatal Encephalopathy
Device: CergenX Wave
The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.
Also known as: eego amplifier
Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life
Time frame: From the enrolment and up to 6 hours after birth
Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.
Time frame: From enrolment of the participant and up to 30 hours after birth
Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.
Time frame: From enrolment of the participant and up to 30 hours after birth
Association between CergenX Wave software and clinical variables including discharge diagnosis
Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses
Time frame: From enrolment of the participant and up to 30 hours after birth
Assessment of healthcare professional (device users) satisfaction with usability of the device.
An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale.
Time frame: From enrolment of the participant and up to 30 hours after birth
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.
Of 50 observational studies under Hypoxia-Ischemia, Brain, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 20. This study's planned 12 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Sep 2026 → Oct 2026, primary completion Sep 2027 → Oct 2027 and completion Sep 2027 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.